how many people are on glp-1 drugs Drug Market: the rapid growth of the diabetes and obesity market The Multi-Sector Impacts of GLP-1RA

Description

[DOI] [PubMed] [Google Scholar] 29.Scott R.V., Bloom S.R

Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus

Global burden of polycystic ovary syndrome among women of childbearing age, 19902021: a systematic analysis using the global burden of disease study 2021

New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov

SGLT2is reduced the risk of major adverse cardiovascular events (MACE) in participants both receiving and not receiving GLP1-RAs, HR 0.81 (95% CI 0.631.03) vs HR 0.90 (95% CI 0.860.94